Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Hall

Showing results (11-20 of 133) with videos related to

Pageof 14
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2005
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamilYing-Hong Wang, David R Jones, Stephen D Hall
Brain Sciences|October 25, 2024
Post-Movement Beta Synchrony Inhibits Cortical ExcitabilityEdward Rhodes, William Gaetz, Jonathan Marsden, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 4, 2004
Mechanism-based inactivation of CYP3A by HIV protease inhibitorsC Steven Ernest, Stephen D Hall, David R Jones
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 1, 2007
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5)David R Jones, Sean Ekins, Lang Li, et al.
Journal of Cognitive Neuroscience|March 1, 2018
Transient Alpha and Beta Synchrony Underlies Preparatory Recruitment of Directional Motor NetworksEdward Rhodes, William C Gaetz, Jonathan Marsden, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2013
Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazoleBing Han, Jialin Mao, Jenny Y Chien, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 8, 2015
Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic modelBoyd Steere, Jessica A Roseberry Baker, Stephen D Hall, et al.
Journal of Clinical Pharmacology|July 12, 2025
Development of a Physiologically Based Pharmacokinetic Model to Evaluate Dosing Regimens of Cyclosporine as a Precipitant of Organic Anion Transporting Polypeptide 1B (OATP1B)- and CYP3A4-Mediated Drug-Drug InteractionsPooja V Hegde, Jessica Rehmel, Stephen D Hall, et al.
European Journal of Clinical Pharmacology|April 5, 2025
A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory markerDavid E Coutant, Jessica Rehmel, Donna M Edwards, et al.
Journal of Pharmaceutical Sciences|October 17, 2017
Monitoring the Phase Behavior of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence TechniquesFrancesco Tres, Stephen D Hall, Michael A Mohutsky, et al.
Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2005
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamilYing-Hong Wang, David R Jones, Stephen D Hall
Brain Sciences|October 25, 2024
Post-Movement Beta Synchrony Inhibits Cortical ExcitabilityEdward Rhodes, William Gaetz, Jonathan Marsden, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 4, 2004
Mechanism-based inactivation of CYP3A by HIV protease inhibitorsC Steven Ernest, Stephen D Hall, David R Jones
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 1, 2007
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5)David R Jones, Sean Ekins, Lang Li, et al.
Journal of Cognitive Neuroscience|March 1, 2018
Transient Alpha and Beta Synchrony Underlies Preparatory Recruitment of Directional Motor NetworksEdward Rhodes, William C Gaetz, Jonathan Marsden, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2013
Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazoleBing Han, Jialin Mao, Jenny Y Chien, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 8, 2015
Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic modelBoyd Steere, Jessica A Roseberry Baker, Stephen D Hall, et al.
Journal of Clinical Pharmacology|July 12, 2025
Development of a Physiologically Based Pharmacokinetic Model to Evaluate Dosing Regimens of Cyclosporine as a Precipitant of Organic Anion Transporting Polypeptide 1B (OATP1B)- and CYP3A4-Mediated Drug-Drug InteractionsPooja V Hegde, Jessica Rehmel, Stephen D Hall, et al.
European Journal of Clinical Pharmacology|April 5, 2025
A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory markerDavid E Coutant, Jessica Rehmel, Donna M Edwards, et al.
Journal of Pharmaceutical Sciences|October 17, 2017
Monitoring the Phase Behavior of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence TechniquesFrancesco Tres, Stephen D Hall, Michael A Mohutsky, et al.
Pageof 14